PILRA hFc Chimera, Human
PILRA HFc Chimera, Human

The purity of PILRA hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

PILRA HFc Chimera, Human

PILRA hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

PILRA hFc Chimera, Human

Alzheimer's disease (AD) is a neurodegenerative disease characterized by a progressive decline in cognitive performance; Mild Cognitive Impairment (MCI) is instead an objective decline in cognitive performance that does not reach pathology. Paired immunoglobulin-like type 2 receptor alpha (PILRA) is a cell surface inhibitory receptor that was recently suggested to be involved in AD pathogenesis. In particular, the arginine-to-glycine substitution in position 78 (R78, rs1859788) was shown to be protective against AD.
Z05753
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
PILRA (Gln20-Ala197)_x000D_
Accession # Q9UKJ1-1		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 47 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 60-68 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • PILRA HFc Chimera, Human
    • PILRA HFc Chimera, Human

    The purity of PILRA hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • PILRA HFc Chimera, Human
    • PILRA HFc Chimera, Human

    PILRA hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Alzheimer's disease (AD) is a neurodegenerative disease characterized by a progressive decline in cognitive performance; Mild Cognitive Impairment (MCI) is instead an objective decline in cognitive performance that does not reach pathology. Paired immunoglobulin-like type 2 receptor alpha (PILRA) is a cell surface inhibitory receptor that was recently suggested to be involved in AD pathogenesis. In particular, the arginine-to-glycine substitution in position 78 (R78, rs1859788) was shown to be protective against AD.
Synonyms PILRA; FDF03; PILRalpha; PILR-alpha

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.